Millipore Sigma Vibrant Logo

70839 Origami™ B(DE3)pLysS Competent Cells - Novagen

View Products on Sigmaaldrich.com
70839
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
70839-3
Récupération des données relatives à la disponibilité...
Disponibilité limitée
Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      Ampoule plast. 0.4 ml
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      Demander le prix
      70839-4
      Récupération des données relatives à la disponibilité...
      Disponibilité limitée
Disponibilité limitée
      En stock 
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
        Pour le restant : Nous vous tiendrons informé
          Pour le restant : Nous vous tiendrons informé
          Nous vous tiendrons informé
          Contacter le Service Clients
          Contact Customer Service

          Flacon en verre 1 ml
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          La quantité minimale doit être un multiple de
          Maximum Quantity is
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          Description
          OverviewOrigami™ B host strains carry the same mutations in trxB and gor as the original Origami strains, except that they are derived from a lacZY mutant of BL21 to enable precise control of expression levels by adjusting the concentration of IPTG. Thus the Origami B strains combine the desirable characteristics of BL21, Tuner™, and Origami strains in one strain background. The mutations in trxB and gor are selectable on kanamycin and tetracycline, respectively; therefore, these strains cannot be used with plasmids that can only selected with kanamycin or tetracycline. These strains also include the lon and ompT deficiences of BL21, which increase protein stability.

          DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

          pLysS strains express T7 lysozyme, which further suppresses basal expression of T7 RNA polymerase prior to induction, thus stabilizing pET recombinants encoding target proteins that affect cell growth and viability.
          Genotype: F- ompT hsdSB(rB- mB-) gal dcm lacY1 ahpC (DE3) gor522:: Tn10 trxB pLysS (CamR, KanR, TetR)


          This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges MilliporeSigma to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.




          This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the 'EMD Product') requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.
          Catalogue Number70839
          Brand Family Novagen®
          References
          Product Information
          Components
          Guaranteed efficiencyGuaranteed efficiency: > 2 x 10⁶ cfu/μg
          Quality LevelMQ100
          Applications
          Biological Information
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Multiple Toxicity Values, refer to MSDS
          Storage ≤ -70°C
          Do not freeze Ok to freeze
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications
          Global Trade Item Number
          Référence GTIN
          70839-3 07790788052836
          70839-4 07790788052843

          Documentation

          Origami™ B(DE3)pLysS Competent Cells - Novagen Certificats d'analyse

          TitreNuméro de lot
          70839

          Brochure

          Titre
          Competent Cell Brochure

          Citations

          Titre
        • Megan M. Kibbey, et al. (2006) Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to IGF-1 binding. Molecular Pharmacology 69, 833-845.
        • James Flint, et al. (2005) Probing the mechanism of ligand recognition in family 29 carbohydrate-binding molecules. Journal of Biological Chemistry 280, 23718-23726.
        • Protocoles Utilisateur

          Titre
          TB009 Competent Cells
          TB053 Academic and Non-profit Laboratory Assurance Letter

          Produits & Applications associés

          Related Products

          Référence Description  
          70836 Origami™ B Competent Cells - Novagen Prix & Disponibilité
          70837 Origami™ B(DE3) Competent Cells - Novagen Prix & Disponibilité
          70911 Origami™ B Competent Cell Set - Novagen Prix & Disponibilité

          Produits associés classés par : Brand Facete

          Catégories

          Life Science Research > Genomic Analysis > Transfection and Protein Expression > Bacterial Expression > Competent Cells for Expression